Meina Quan

Meina Quan

Auto-generated profile, based on publicly available information

Meina Quan

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Phenomics
Verified
Journal Article
Open access
PDF file
MQMeina Quan
Meina Quan
SCShuman Cao
Shuman Cao
QWQi Wang
Qi Wang
SWShiyuan Wang
Shiyuan Wang
JJJianping Jia
Jianping Jia
Years of intensive research has brought us extensive knowledge on the genetic and molecular factors involved in Alzheimer's disease (AD). In addition to the mutations in the three main causative genes of familial AD (FAD) including presenilins and amyloid precursor protein genes, studies have identified several genes as the most plausible genes for the onset and progression of FAD, such as triggering receptor expressed on myeloid cells 2, sortilin-related receptor 1, and adenosine triphosphate-binding cassette transporter subfamily A member 7. The apolipoprotein E ε4 allele is reported to be the strongest genetic risk factor for sporadic AD (SAD), and it also plays an important role in FAD. Here, we reviewed recent developments in genetic and molecular studies that contributed to the understanding of the genetic phenotypes of FAD and compared them with SAD. We further reviewed the advancements in AD gene therapy and discussed the future perspectives based on the genetic phenotypes.

31 May 2012 in Journal of Computational Neuroscience
Verified
Journal Article
Closed access
PDF file
CZChenguang Zheng
Chenguang Zheng
MQMeina Quan
Meina Quan
TZTao Zhang
Tao Zhang

1 February 2014 in Behavioural Brain Research
Verified
Journal Article
Closed access
ESElif M. Sikoglu
Elif M. Sikoglu
MHMeghan E. Heffernan
Meghan E. Heffernan
KTKelly Tam
Kelly Tam
KSKenneth M. Sicard
Kenneth M. Sicard
BBBernt T. Bratane
Bernt T. Bratane
JKJean King
Jean King

1 January 2020 in Neurobiology of Aging
Verified
Journal Article
Closed access
QQQiongqiong Qiu
Qiongqiong Qiu
LJLongfei Jia
Longfei Jia
QWQi Wang
Qi Wang
LZLina Zhao
Lina Zhao
HJHongmei Jin
Hongmei Jin
JJJianping Jia
Jianping Jia

25 February 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
JDJiayi Ding
Jiayi Ding
MQMeina Quan
Meina Quan
PZPeixi Zang
Peixi Zang
JJJianping Jia
Jianping Jia
Background: Metabolic syndrome (MetS) was associated with an increased incidence of mild cognitive impairment (MCI) and progression to dementia. Objective: To study the associations between MetS indicators and cerebrospinal fluid (CSF) biomarkers in the participants. Methods: 61 normal cognition, 66 mild MCI, and 135 dementia participants were included in our study, with the results of lumbar puncture and peripheral blood biochemistry. The CSF levels of amyloid-β (Aβ) 42 protein, total tau protein, phosphorylated tau protein, and Aβ 42/40 ratio, were selected as the biomarkers. The body mass index, the plasma high density lipoprotein cholesterol, uric acid, low density lipoprotein cholesterol, triglyceride, and homocysteine levels were selected as indicators of MetS. Linear regression model was used to analyze the correlation in all participants and different cognitive stages, controlling for age, gender, and APOE genotype. Results: Our study showed that MetS indicators were associated with CSF biomarkers in participants after adjusting for possible confounding factors, including age, gender, and APOE genotype. The results of our grouping analysis further supported the potential association between plasma MetS indicators and CSF biomarkers in three group. We found that the dementia group showed the greatest correlation coefficient. Conclusions: The CSF pathological proteins concentrations were associated with MetS indicators, and the correlation coefficient were greater in the dementia stage. These findings suggest that regulating peripheral metabolism may affect the level of pathological proteins in the brain to improve cognitive impairment.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
JJJianping Jia
Jianping Jia
YLYan Li
Yan Li
DLDiyang Lv
Diyang Lv
HJHaishan Jiao
Haishan Jiao
YSYuqing Shi
Yuqing Shi
MQMeina Quan
Meina Quan
Background: Most of the FDA approved drugs for AD are symptom driven and effects are limited. Because AD is a complex disease involving multiple pathological changes, such as senile plaques formed by amyloid‐β (Aβ) deposition, neurofibrillary tangles caused by tau hyperphosphorylation, microglia‐evoked neuroinflammation, synaptic degeneration, and blood‐brain barrier (BBB) disruption. While the current anti‐dementia drugs are mostly single targets, Chinese medicines have great development potential considering their multi‐target anti‐dementia components.Method: Several Chinese medicine monomers, including cryptotanshinone (CTS), pterostilbene (PTE), Ginsenoside Compound K (GCK), and glabridin (Gla) were selected to test their safety and efficacy in AD cell models, and to further explore their possible molecular mechanisms and target of action. Aβ42 oligomers (AβO) were used to establish AD cell models. The cytotoxicity of AβO as well as protective effects of Chinese medicine monomers on cell models were evaluated using the MTT assay. The molecular mechanisms and pathways were tested using qRT‐PCR, ELISA, Western blot and immunofluorescence.Result: AβO induced cell injury, apoptosis, and generation of intracellular reactive oxygen species (ROS). In AβO‐induced cell models, CTS significantly reduced tau hyperphosphorylation at Ser202, Ser404, Thr181, and Thr231, and increased the levels of PSD95 and synaptophysin; PTE attenuated cell injury, apoptosis, and ROS generation; GCK diminished inflammatory cytokine production; Gla attenuated cell injury (figure1). Further study found that their mechanisms of action include PI3K/Akt/GSK3β pathway (figure2), BBB permeability and tight junction scaffold protein (figure3), as well as NF‐kB pathway via LRP1 activation (figure4), respectively.Conclusion: These results provides rational basis for the therapeutic application of Chinese medicine monomers in the treatment of AD, and support further evaluation of these multi‐target action potential in AD treatment.